Quality by Design—Case Study Vaccines| © 2010 PRTM Proprietary CONFIDENTIAL | 1 Quality by Design – Vaccine Case Study Last year, the CMC-Biotech Working.

Slides:

Advertisements

Similar presentations

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

Advertisements

FDA/Industry Statistics Workshop Washington D.C. September 27-29, 2006

17 September 2007ISO TC215 WG6 Brisbane1 Identification of Medicinal Products & Pharmacovigilance Task Forces.

VALIDATION OF COMPUTERISED SYSTEMS IN THE PHARMACEUTICAL INDUSTRY Matt Safi Product manager.

4 th Kitasato-Harvard Symposium: Summary and Conclusions Stephen Lagakos Harvard School of Public Health.

Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker

Victoria Cassens, Purdue University Accepted Labels State Tracking and Repository: ALSTAR.

Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

RACE TO EXCELLENCE This presentation provides guidance and tools for participation in the 2011 Race.

Implementation of Quality-by-Design: ONDQA Initiatives Advisory Committee for Pharmaceutical Science October 5, 2006 Chi-wan Chen, Ph.D. Deputy Director.

Perspectives on New Paradigms of Risk and Compliance in Pharmaceutical Development: Quality by Design, PAT, and Design Space David J. Cummings OPS Quality.

Consulting for Life Sciences 1 Confidential October 14, 2014 Strategic Science and Technology Capabilities Discussion

Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.

McGraw-Hill/Irwin ©2009 The McGraw-Hill Companies, All Rights Reserved Marketing Concept, Customer Needs, American Marketing Association, Customers, Employees,

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.

Chemical Industries Council of Malaysia Responsible Care  APEC CHEMICAL DIALOGUE 9th Asia Pacific Responsible Care Conference November 16, 2005 * EDSA.

Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.

April 11, 2007 Prepared by the North American Energy Standards Board 1 North American Energy Standards Board Standards Development Process.

Pharma.be The Initiative to Promote Clinical Trials in Belgium Key Performance Indicators: Impact on Clinical Research of European Legislation Square –

Scientific Data for Evidence- Based Drug Regulation Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration.

Doc.: IEEE f Submission IEEE f March 2010 Tim Harrington, Zebra Enterprise SolutionsSlide 1 Project: IEEE P

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

INTRODUCTION TO RA.

Implementing Shared Inspection Management Systems Insights from recent WBG research John R. Wille WBG Investment Climate Advisory Services Amman, Jordan.

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. THE PRACTICE OF REGULATORY INTELLIGENCE: CASE STUDIES OMICS 5 th International Pharmaceutical.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

CONFIDENTIAL ©2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. REGULATORY INTELLIGENCE: INDUSTRY’S BEST PRACTICE OMICS 5 th International Pharmaceutical.

HERA STAKEHOLDERS WORKSHOP-11 JULY FUTURE CHEMICALS POLICY and HERA Anne-Marie Rodeyns, A.I.S.E. Deputy Director 11 July 2002.

1 An Update on ICH Guideline Q8 – Pharmaceutical Development FDA Advisory Committee for Pharmaceutical Science: 5 Oct 2006 Dr John C Berridge Senior Regulatory.

HUG Regulatory/Government Affairs Team Jackie Elkin, Medtronic June 20, 2005.

PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.

Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.

Molecule-to-Market-Place Quality

Workshop Session 3 Questions 1 How would a control strategy look different in a traditional submission vs a QbD submission? How would parameters that are.

10:00 A.M. – Noon 7 June 2004 ICH Quality Plenary Meeting.

Generic Industry’s Perspective on the New GMP Initiative May 21, 2003 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance.

Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.

Catalysts for enactment of PDUFA  Amendments to FD&C Act  Origin of modern drug development process  Requirement that drugs be shown to be safe.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

1 Nanoscale Materials Stewardship Program Environmental Summit May 20, 2008 Jim Alwood Chemical Control Division Office of Pollution Prevention and Toxics.

CDISC – 17/12/2012 Carine Javierre Nathalie SABIN.

ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

ICH Quality Topics Update

Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

2010 James Fitzgerald Senior Advisor, Medicines and Health Technologies PAHO/WHO rd St Washington DC USA International Cooperation in Quality.

IDMP Overview December 2015.

Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.

Top Business IT Challenges of 2016

WP3 - Evaluation and proposal selection

An Update on ICH Guideline – Pharmaceutical Development

Pharmaceutical Quality in the 21st Century

Lessons Learned: Past Present and Future Japan-USA Regulatory Interactions Erica Takai, PhD US Food and Drug Administration

Quality System.

NASs approval time by therapeutic area:

PhUSE European CSS Working Group

PhUSE Computational Science

Percentage Key Message

Submission Title: [Proposed project timeline]

Innovative Medicines Initiative:

New active substance median approval time for six regulatory authorities in Key messages The last decade, , saw a continuation.

ApprenticeshipNC Regional Collaboration and Expansion Project

Jul 12, /12/10 Project: IEEE P Working Group for Wireless Personal Area Networks (WPANs) Submission Title: IG DEP Dependable Closing Report.

Submission Title: [UWB Forum Liaison Report]

MIPC Proposal – <INSERT TITLE> for <INSERT INDUSTRY>

Out of the 52 NASs approved by all six authorities during :

Presentation transcript:

Quality by Design—Case Study Vaccines| © 2010 PRTM Proprietary CONFIDENTIAL | 1 Quality by Design – Vaccine Case Study Last year, the CMC-Biotech Working Group (CMC_BWG) completed a case study to exemplify the application of Quality by Design to biopharmaceutical development  “A-Mab Case Study” was well received & has served as a substrate to open up the dialogue between industry and regulatory agencies on the challenges of implementing QbD for biotech products Following on this success, facilitators from CMC-BWG have been approached to pull together a similar industry consortium (CMC-VWG) to promote QbD for vaccines Proposed Timeline Contact Vaccine manufacturersJuly 2010 Contact Regulatory AgenciesJuly –August 2010 Set-up NDAs and AgreementsComplete by Sep 15 th Kick- OffOctober 1 st

Quality by Design—Case Study Vaccines| © 2010 PRTM Proprietary CONFIDENTIAL | 2 A Vaccine QbD Case Study: What Is It? Word document co-authored by a consortium of company representatives to promote the implementation of ICH QbD guidelines in vaccine development  Will be made available to the public  Focus on science and risk-based applications  Forward looking—focused on what individuals would like to do in the future versus what they currently do now  Multiple perspectives offered as a result of the cross-company and cross-functional interactions Regulators (FDA, PMDA, EMA principals) will be invited to contribute to the case study, but not to endorse it  Their insight into QbD application to vaccines would add immensely to its value Targeting top Vaccine Manufacturers  To keep the group manageable, the first six companies to sign up by the September 1st deadline will be accepted into the program The Case Study is not… A mock CMC submission or a “Gold Standard” for how things should be done Attempt to receive an endorsement from the regulatory agencies An initiative that requires companies to share intellectual property—specific process operations, real results, etc. The Case Study is not… A mock CMC submission or a “Gold Standard” for how things should be done Attempt to receive an endorsement from the regulatory agencies An initiative that requires companies to share intellectual property—specific process operations, real results, etc.

Quality by Design—Case Study Vaccines| © 2010 PRTM Proprietary CONFIDENTIAL | 3 Contacts Sam Venugopal Principal T F M Castro Street Suite 400 Mountain View, CA U.S.A. John Berridge Pharmaceutical Ccnsultant T Bracklyn, St. Clare Road Walmer Deal CT14 7QB